JP2024539735A5 - - Google Patents
Info
- Publication number
- JP2024539735A5 JP2024539735A5 JP2024529362A JP2024529362A JP2024539735A5 JP 2024539735 A5 JP2024539735 A5 JP 2024539735A5 JP 2024529362 A JP2024529362 A JP 2024529362A JP 2024529362 A JP2024529362 A JP 2024529362A JP 2024539735 A5 JP2024539735 A5 JP 2024539735A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- administered
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280067P | 2021-11-16 | 2021-11-16 | |
| US63/280,067 | 2021-11-16 | ||
| PCT/US2022/050163 WO2023091524A1 (en) | 2021-11-16 | 2022-11-16 | Therapeutic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539735A JP2024539735A (ja) | 2024-10-29 |
| JP2024539735A5 true JP2024539735A5 (https=) | 2025-12-02 |
Family
ID=86397745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529362A Pending JP2024539735A (ja) | 2021-11-16 | 2022-11-16 | 治療用化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250099483A1 (https=) |
| EP (1) | EP4433062A4 (https=) |
| JP (1) | JP2024539735A (https=) |
| IL (1) | IL312745A (https=) |
| WO (1) | WO2023091524A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US20110263569A1 (en) * | 2007-08-22 | 2011-10-27 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| EP2708535A1 (en) * | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2021222739A1 (en) * | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| US11717526B2 (en) * | 2021-05-20 | 2023-08-08 | Armgo Pharma, Inc. | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
-
2022
- 2022-11-16 WO PCT/US2022/050163 patent/WO2023091524A1/en not_active Ceased
- 2022-11-16 IL IL312745A patent/IL312745A/en unknown
- 2022-11-16 JP JP2024529362A patent/JP2024539735A/ja active Pending
- 2022-11-16 EP EP22896448.2A patent/EP4433062A4/en active Pending
-
2024
- 2024-05-13 US US18/662,117 patent/US20250099483A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2201754C2 (ru) | Фармацевтический состав, способ его получения, способ лечения психотических состояний и гиперактивности | |
| JP3745621B2 (ja) | 持続放出型ラノラジン製剤 | |
| US6479496B1 (en) | Methods for treating angina with ranolazine | |
| AU2021269434A1 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| JP5344620B2 (ja) | オルメサルタンメドキソミル及びアムロジピンの固形製剤 | |
| EP2033633A2 (en) | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | |
| CN102056603A (zh) | 决奈达隆用于预防持续性心房纤颤 | |
| US20080027032A1 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
| JP2005255687A (ja) | リゼドロネート遅延放出組成物 | |
| EP2205279B1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
| CN109890366A (zh) | 治疗心血管疾病的组合药物及其制备和使用方法 | |
| US11382866B2 (en) | Fixed dose pharmaceutical composition of valsartan and sacubitril | |
| TW202423423A (zh) | 治療非阻塞性肥厚性心肌病之方法 | |
| EP1891937A1 (en) | Galenic formulations of aliskiren | |
| AU764304B2 (en) | Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders | |
| US6849661B2 (en) | Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil | |
| CN102056602A (zh) | 决奈达隆用于预防心脏复律 | |
| KR100623122B1 (ko) | 조합 제제로서의 엔도텔린 길항제 및 베타-수용체 차단제 | |
| EP2837380B1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| JP2024539735A5 (https=) | ||
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| EP1465607B1 (fr) | Compositions pharmaceutiques a liberation modifiee | |
| JP7137852B2 (ja) | ９‐β‐Ｄ‐アラビノフラノシルヒポキサンチンによる不整脈治療 | |
| CN113456607A (zh) | 一种沙库巴曲缬沙坦钠单层渗透泵控释片及其制备方法 | |
| JP2024519917A5 (https=) |